|
1
|
Grothey A, Hedrick EE, Mass RD, Sarkar S,
Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM and Sargent DJ:
Response-independent survival benefit in metastatic colorectal
cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol.
26:183–189. 2008. View Article : Google Scholar
|
|
2
|
Langer CJ, Socinski MA, Patel JD, Sandler
AB, Schiller JH, Leon L, Hazard SJ and Ramalingam SS: Isolating the
role of bevacizumab in elderly patients with previously untreated
nonsquamous non-small cell lung cancer: Secondary analyses of the
ECOG 4599 and pointbreak trials. Am J Clin Oncol. 39:441–447. 2016.
View Article : Google Scholar
|
|
3
|
Cheng AL, Qin S, Ikeda M, Galle PR,
Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, et al:
Updated efficacy and safety data from IMbrave150: Atezolizumab plus
bevacizumab vs. sorafenib for unresectable hepatocellular
carcinoma. J Hepatol. 76:862–873. 2022. View Article : Google Scholar
|
|
4
|
Redondo A, Colombo N, McCormack M, Dreosti
L, Nogueira-Rodrigues A, Scambia G, Lorusso D, Joly F, Schenker M,
Ruff P, et al: Primary results from CECILIA, a global single-arm
phase II study evaluating bevacizumab, carboplatin and paclitaxel
for advanced cervical cancer. Gynecol Oncol. 159:142–149. 2020.
View Article : Google Scholar
|
|
5
|
You B, Purdy C, Copeland LJ, Swisher EM,
Bookman MA, Fleming G, Coleman R, Randall LM, Tewari KS, Monk BJ,
et al: Identification of patients with ovarian cancer experiencing
the highest benefit from bevacizumab in the first-line setting on
the basis of their tumor-intrinsic chemosensitivity (KELIM): The
GOG-0218 validation study. J Clin Oncol. 40:3965–3974. 2022.
View Article : Google Scholar
|
|
6
|
Holash J, Davis S, Papadopoulos N, Croll
SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, et
al: VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc
Natl Acad Sci USA. 99:11393–11398. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Apte RS, Chen DS and Ferrara N: VEGF in
signaling and disease: Beyond discovery and development. Cell.
176:1248–1264. 2019. View Article : Google Scholar
|
|
8
|
Von Minckwitz G, Puglisi F, Cortes J,
Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang
I, Ciruelos E, et al: Bevacizumab plus chemotherapy versus
chemotherapy alone as second-line treatment for patients with
HER2-negative locally recurrent or metastatic breast cancer after
first-line treatment with bevacizumab plus chemotherapy (TANIA): An
open-label, randomised phase 3 trial. Lancet Oncol. 15:1269–1278.
2014. View Article : Google Scholar
|
|
9
|
Zhang T, Yang Y, Cheng G, Chen P and Bi N:
Tracheoesophageal fistula associated with bevacizumab after
thoracic radiotherapy in non-small cell lung cancer: A case report.
Medicine (Baltimore). 99:e198782020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Olawaiye AB, Baker TP, Washington MK and
Mutch DG: The new (version 9) American joint committee on cancer
tumor, node, metastasis staging for cervical cancer. CA Cancer J
Clin. 71:287–298. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niu G and Chen X: Vascular endothelial
growth factor as an anti-angiogenic target for cancer therapy. Curr
Drug Targets. 11:1000–1017. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sullivan LA and Brekken RA: The VEGF
family in cancer and antibody-based strategies for their
inhibition. MAbs. 2:165–175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thawani R, Thomas A and Thakur K:
Tracheomediastinal fistula: Rare complication of treatment with
bevacizumab. Cureus. 10:e24192018.PubMed/NCBI
|
|
15
|
Zhou Y, Rui Y, Xu P, Yang Q, Luo X, Yi B
and Zheng Y: Clinical analysis of 8 cases of gastrointestinal
perforation caused by bevacizumab. Chin J Bases Clin Gen Surg.
28:516–519. 2021.(In Chinese).
|
|
16
|
Goodgame B, Veeramachaneni N, Patterson A
and Govindan R: Tracheo-esophageal fistula with bevacizumab after
mediastinal radiation. J Thorac Oncol. 3:1080–1081. 2008.
View Article : Google Scholar
|
|
17
|
Gore E, Currey A and Choong N:
Tracheoesophageal fistula associated with bevacizumab 21 months
after completion of radiation therapy. J Thorac Oncol. 4:1590–1591.
2009. View Article : Google Scholar
|
|
18
|
Nishie K, Yasuo M, Kitaguchi Y, Kobayashi
N, Tateishi K, Ushiki A, Urushihata K, Yamamoto H, Ideura G and
Hanaoka M: Bevacizumab-induced tracheoesophageal fistula in a
patient suffering from lung cancer with bulky subcarinal lymph
node: A case report. Nagoya J Med Sci. 80:129–134. 2018.
|
|
19
|
Wang T, Thakur A and Chen B:
Bevacizumab-induced esophageal pleural fistula during maintenance
therapy without radiation in lung cancer. BMC Pulm Med. 21:3842021.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang Y, Feng W, Gao LT, Cai XW, Liu Q,
Zhu ZF, Fu XL and Yu W: Long-term follow-up of a phase I/II trial
of radiation dose escalation by simultaneous integrated boost for
locally advanced esophageal squamous cell carcinoma. Radiother
Oncol. 159:190–196. 2021. View Article : Google Scholar
|
|
21
|
Mangoni M, Vozenin MC, Biti G and Deutsch
E: Normal tissues toxicities triggered by combined anti-angiogenic
and radiation therapies: Hurdles might be ahead. Br J Cancer.
107:308–314. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seiwert TY, Connell PP, Mauer AM, Hoffman
PC, George CM, Szeto L, Salgia R, Posther KE, Nguyen B, Haraf DJ
and Vokes EE: A phase I study of pemetrexed, carboplatin, and
concurrent radiotherapy in patients with locally advanced or
metastatic non-small cell lung or esophageal cancer. Clin Cancer
Res. 13:515–522. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee RJ, Workman AD, Carey RM, Chen B,
Rosen PL, Doghramji L, Adappa ND, Palmer JN, Kennedy DW and Cohen
NA: Fungal aflatoxins reduce respiratory mucosal ciliary function.
Sci Rep. 6:332212016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Banz M, Stallmach A, Gaßler N, Schulze PC,
Fritzenwanger M, Cornely O, Kurzai O and Pletz MW: Fatal pulmonary
hemorrhage, pneumothorax and skin necrosis caused by IRIS to an
Aspergillus flavus infection in a young patient with
metamizole associated agranulocytosis. Infection. 52:685–690. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ladna M and George J: Large esophageal
intramural hematoma after solid food ingestion in a patient without
identifiable inherited or acquired coagulopathy. ACG Case Rep J.
10:e010672023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spigel DR, Hainsworth JD, Yardley DA,
Raefsky E, Patton J, Peacock N, Farley C, Burris HA III and Greco
FA: Tracheoesophageal fistula formation in patients with lung
cancer treated with chemoradiation and bevacizumab. J Clin Oncol.
28:43–48. 2010. View Article : Google Scholar
|
|
27
|
McColl KEL: What is causing the rising
incidence of esophageal adenocarcinoma in the West and will it also
happen in the East? J Gastroenterol. 54:669–673. 2019. View Article : Google Scholar
|
|
28
|
Hines MT, Crisman MV, Kohn CW, Hansen B,
Hinchcliff KW, Foreman JH, Beard LA and Rush BR: Clinical Approach
to Commonly Encountered Problems. Equine Internal Medicine. 2nd
edition. Elsevier Inc; pp. 111–168. 2004, View Article : Google Scholar
|
|
29
|
Dwivedi S, Schrickel EB, Siddiqui F,
O'Brien J and Kruer J: Esophageal microperforation due to calcified
mediastinal lymph node leading to tracheoesophageal fistula. Case
Rep Gastrointest Med. 2016:97471932016.PubMed/NCBI
|
|
30
|
Haanen J, Obeid M, Spain L, Carbonnel F,
Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, et al:
Management of toxicities from immunotherapy: ESMO clinical practice
guideline for diagnosis, treatment and follow-up. Ann Oncol.
33:1217–1238. 2022. View Article : Google Scholar
|
